Dividend Policy and Shareholder Returns
Dividend History: Coherus has never declared or paid a cash dividend on its common stock, and it does not anticipate paying dividends in the foreseeable future (www.sec.gov). Instead, the company has consistently reinvested its capital into product development and commercialization efforts. This policy is typical for clinical-stage and growth-oriented biotech companies, which prioritize R&D and pipeline advancement over near-term shareholder payouts. Consequently, CHRS’s dividend yield is 0%, and traditional REIT metrics like FFO/AFFO are not applicable. Coherus has also not engaged in share buybacks; rather, recent capital allocation has gone toward debt reduction (notably repurchasing its own convertible notes, discussed below) and funding pipeline programs. Any “return” to shareholders thus far would need to come from stock price appreciation, which has been challenging given the company’s losses and the sector’s volatility (CHRS shares traded in the mid-teens a few years ago but fell into the low-single-digits by 2024 amid biosimilar price competition and cash burn (www.sec.gov) (www.tipranks.com)). Management’s stance is that “any potential return to stockholders will be limited to stock price appreciation” for the foreseeable future (www.sec.gov).
Financial Position: Leverage, Debt Maturities, and Coverage
Debt Reduction: Coherus entered 2024 with a significant debt load, but it has since dramatically deleveraged by using asset-sale proceeds to retire debt. As of December 31, 2024, the company’s financial liabilities had dropped to $293.7 million from $473.4 million a year prior (www.sec.gov) (www.sec.gov). This improvement was driven by paying down a huge term loan and tackling its convertible notes:
- Convertible Notes (1.5% due April 2026): Coherus had $230 million of convertible senior notes maturing in April 2026 (www.sec.gov). In April 2025, the company struck agreements to repurchase ~$170 million of these notes for cash at par (conditioned on the UDENYCA sale closing) (www.globenewswire.com). Following the UDENYCA divestiture in April 2025, Coherus confirmed it would buy back the remaining $60 million of notes, effectively retiring the entire $230M issue (www.globenewswire.com). This preemptive take-out of the converts was funded by the Intas upfront payment; management explicitly earmarked part of the $483.4 million cash inflow to fully repay the convertible debt (www.biospace.com). The note repurchases eliminate a looming 2026 maturity and annual interest payments of ~$3.45 million (www.sec.gov) (www.sec.gov). It’s worth noting the conversion price on these notes was ~$19.26 per share (www.sec.gov) – far above CHRS’s current stock price – so conversion was unlikely. Retiring the debt at 100% of face saved shareholders from potential dilution while also relieving interest cost.
- Term Loan (Senior Secured, due 2029): In May 2024, Coherus refinanced its prior credit facility with a new $38.7 million term loan maturing May 8, 2029 (www.sec.gov) (www.sec.gov). The loan accrues interest at a fixed 8.0% plus three-month SOFR (floating), which currently puts the coupon in the low-teens% range (www.sec.gov). Crucially, this 2029 loan carried interest-only quarterly payments until maturity, with no principal amortization (www.sec.gov). Coherus used the $37.5 million net proceeds from this loan (along with cash from asset sales) to fully pay off its previous $250M term loan facility in 2024 (www.sec.gov) (www.sec.gov). Thanks to the CIMERLI and UDENYCA sales, Coherus was able to extinguish the old 2027 loan early, incurring a one-time $12.6 million debt extinguishment loss (prepayment fees and unamortized costs) (www.sec.gov) (www.sec.gov). The new 2029 loan is much smaller in size, but it is secured by substantially all company assets and comes with covenants – for example, Coherus must maintain certain minimum cash balances under this loan agreement (www.sec.gov) (www.sec.gov). As of year-end 2024, the gross term loan balance was $38.66 million (carrying value ~$36.7M net of discounts) (www.sec.gov). Management has not indicated plans to pay this loan off early (which would incur prepayment premiums of up to 10% in the first 3 years) (www.sec.gov) (www.sec.gov). Given Coherus’s ample cash (see Liquidity below), this debt is manageable, and waiting out the lockout period could avoid hefty make-whole fees.
- Royalty/Revenue Participation Obligation: In addition to formal debt, Coherus raised $37.5 million in May 2024 by selling a percentage of future UDENYCA and LOQTORZI sales to an investment firm (www.sec.gov). This created a “Revenue Purchase and Sale Agreement” liability carried at ~$28.7 million on the 12/31/24 balance sheet (www.sec.gov). The UDENYCA divestiture triggered Coherus to buy out most of this royalty obligation – in fact, $49.1 million of the Intas proceeds were allocated to terminate UDENYCA-related royalty streams (www.biospace.com). According to the company, this payment would cover “the majority” of that liability’s balance (www.sec.gov). We infer that Coherus essentially paid a premium to free itself (and Intas) from any future UDENYCA revenue-sharing, while any remaining portion of the revenue interest (tied to LOQTORZI sales) is now minimal or has been renegotiated. Bottom line: Coherus used the asset sale windfall not only to cut traditional debt but also to clean up encumbrances on its key assets.
Maturities: Following these actions, Coherus has no significant debt maturities until 2029. The $230M convert that was due in 2026 is effectively gone, and the only long-term debt is the 2029 term loan. The convertible note repurchase did rely on closing the UDENYCA sale, but that transaction completed on April 11, 2025 (www.biospace.com) (www.biospace.com). With that closing, Coherus received the full $483.4M cash (including payment for inventory) and transitioned the UDENYCA business to Intas’s Accord BioPharma division (www.biospace.com) (www.biospace.com). Thus, Coherus has addressed all near-term refinancing risks. By extending its debt profile out to 2029 and concurrently boosting cash reserves (see below), the company has bought itself multiple years of runway to execute on its oncology programs without the overhang of looming debt deadlines.
Interest Coverage: Prior to deleveraging, Coherus’s interest coverage was very weak – the company was not generating enough operating profit to cover interest expense. For full-year 2023, Coherus had $35.4 million in interest expense on its term loans alone (www.sec.gov) (reflecting the high debt and interest rates before refinancing), plus roughly $4.8 million on the convertible notes (www.sec.gov). These ~$40 million of annual interest costs far exceeded Coherus’s EBIT in 2023, which was negative due to heavy R&D and SG&A. Even in 2024, Coherus’s $28.5 million net income was entirely attributable to one-time gains on asset sales (www.sec.gov) – underlying operations were still loss-making. Excluding the $176.6 million in divestiture gains, Coherus would have posted a deep net loss in 2024, meaning it could not have covered ~$16 million of interest expense from business-as-usual earnings (www.sec.gov) (www.sec.gov). However, going forward interest coverage is markedly improved now that most debt has been eliminated:
- With the 2027 term loan gone and the 2026 convert repaid, the annual cash interest burden will drop by ~75%. The remaining 2029 term loan at ~$38.7M accrues roughly $5–6 million of interest per year (assuming ~13% interest). By contrast, 2023 interest was around $40M as noted. This dramatic reduction means Coherus’s interest obligations can likely be serviced out of its cash reserves and any LOQTORZI revenue, even if the company continues to report operating losses near-term.
- Cash Runway: Coherus’s liquidity is ample relative to its modest interest needs. At Q2 2025 quarter-end, Coherus had $238 million in cash, equivalents and investments on its balance sheet (investors.coherus.com). The Intas deal left the company with a “$250 million post-close cash balance” in April 2025 (www.biospace.com) (www.biospace.com) (after debt paydowns and transaction costs), which management expects is sufficient to fund operations “over two years into 2027”, past the next major clinical data readouts (www.biospace.com) (investors.coherus.com). In other words, Coherus does not anticipate needing to raise additional capital or debt at least until after it obtains Phase 2 results for its oncology candidates in 2026. This healthy cash buffer ensures that interest payments (roughly $1–1.5M per quarter now) are easily covered for the foreseeable future.
- Covenant Cushion: As noted, the 2029 loan requires Coherus to maintain a certain cash minimum (exact amount undisclosed). With ~$238M in hand versus only ~$37M in term debt, the net leverage is effectively zero – Coherus holds far more cash than debt. Thus, the covenant is unlikely to constrain operations unless the company’s cash burn accelerates dramatically. Management even indicated in its 10-K that regardless of whether the UDENYCA sale closed, they believed existing liquidity and incoming product revenues would fund at least 12 months of operations from the March 2025 filing date (www.sec.gov). In summary, Coherus’s balance sheet flip – from leveraged to net cash positive – has removed the financial distress risk and given it breathing room to focus on drug development.
Valuation and Performance Metrics
Earnings & Cash Flow: Traditional valuation metrics for Coherus are in flux due to the business model shift and one-time transactions. Historically, Coherus generated significant revenue from its biosimilars – for example, FY2023 net revenue was $257.2 million (www.biospace.com), split roughly between UDENYCA (50%) and CIMERLI (49%) with a token amount from YUSIMRY© (adalimumab biosimilar) and other sources (www.biospace.com). Despite that revenue base, high operating costs (R&D for new drugs and SG&A for commercial launches) meant Coherus recorded net losses in most years. The company has an accumulated deficit of ~$1.6 billion as of end-2024 (www.sec.gov). The few exceptions were 2019–2020 (when UDENYCA’s early success drove one-time profitability) and 2024 (when asset sale gains created a paper profit) (www.sec.gov). Going forward, Coherus’s P&L will look very different: it has shed nearly all revenue from biosimilars (discontinued ops), and its top line will now be driven primarily by LOQTORZI sales and collaboration/license income. In Q1 2025, LOQTORZI – which launched in the U.S. in early 2024 for a rare cancer (nasopharyngeal carcinoma) – generated $7.3 million net revenue (www.nasdaq.com). By Q2 2025, LOQTORZI sales grew 36% sequentially to $10.0 million (investors.coherus.com). Annualizing Q2, one might expect ~$40–50M revenue in 2025 from LOQTORZI if growth continues. Thus, 2025 revenues will be far below 2023’s, reflecting the divestitures, but LOQTORZI is a growing starting point (and new indications or combo uses could expand its market). Overall, Coherus will likely report net losses in 2025–2026 as it invests in trials and builds the oncology franchise, making metrics like P/E not meaningful (the trailing P/E is negative (www.tipranks.com)). Instead, investors are valuing CHRS on revenue multiples, pipeline potential, and cash assets.
Price/Sales and Enterprise Value: At the current share price, Coherus’s valuation appears modest relative to its assets: by late 2025 the stock was trading around $1.40–1.50 per share (stockanalysis.com). This equates to a market capitalization of roughly $160–170 million (with ~116 million shares outstanding (www.sec.gov) (www.sec.gov)). Notably, this market cap was on par with or even below Coherus’s cash on hand – which was $238M in mid-2025 and expected to be ~$200+ million by year-end after covering all note repurchases (investors.coherus.com) (www.biospace.com). In other words, the enterprise value (EV) of Coherus (market cap minus net cash) has been hovering near zero. The market is assigning little to no value to the ongoing business and pipeline, likely due to skepticism about future success (www.tipranks.com). For perspective, at $165M market cap vs. ~$40M estimated 2025 sales, CHRS trades at ~4x forward Price/Sales. However, this simple P/S doesn’t capture the story, since current sales are only from one small indication. If Coherus’s oncology strategy succeeds, sales could scale significantly (along with milestone payments), rendering the current valuation low. Conversely, the market-implied outlook suggests that investors fear the cash will be consumed by R&D without yielding a blockbuster – hence effectively valuing the pipeline near zero after backing out cash. This is common for early-stage biotech: until there’s clearer evidence of clinical or commercial traction, the stock may languish at a discount to intrinsic value.
For a more nuanced valuation, consider enterprise value to cash: CHRS’s EV is effectively negative if using mid-2025 figures (EV ≈ $160M mkt cap – $238M cash = –$78M). A negative EV signals that either the stock is undervalued (if the pipeline has worth) or the market expects a significant cash burn that nullifies current cash. Peer Comparison: Pure-play immuno-oncology peers of similar size are few, but small-cap biotech companies with one approved drug and pipeline often trade at 2×–5× EV/revenue in early years. Coherus at ~4× sales is in that range if we only count LOQTORZI’s current niche revenue. Importantly, Coherus’s $250M cash cushion gives it an EV/Revenue of essentially 0 for now – reflecting that cash is the main component of its valuation. In summary, valuation is at a crossroads: the downside appears buffered by the strong balance sheet, while the upside hinges on executing the pipeline to justify a higher multiple on future sales. Any signs of pipeline de-risking (successful trial data in 2026, new partnerships) or LOQTORZI revenue traction could lead to a substantial re-rating of the stock’s EV. Conversely, lack of progress would see the company gradually spending down its cash, which the stock price seems to already imply.
Key Risks and Red Flags
Pipeline and R&D Risk: The foremost risk is that Coherus’s bold pivot to immuno-oncology may not pay off. The company’s pipeline – featuring CHS-114 (a cytolytic anti-CCR8 antibody) and casdozokitug (an IL-27 cytokine antagonist) – is in Phase 1/2 development (investors.coherus.com). These are novel mechanisms with unproven clinical benefit, and trial failures or delays would significantly impair Coherus’s outlook. Investors should be prepared for clinical trial volatility: data readouts for both CHS-114 and casdozokitug are expected in 1H 2026 (investors.coherus.com) (investors.coherus.com). Negative results could leave Coherus with an expensive PD-1 drug but no differentiating combination therapies, undercutting its strategy. Even positive data might require large Phase 3 trials that are beyond Coherus’s financial or operational capacity – likely necessitating a partner or additional capital. This binary clinical risk is inherent in Coherus’s valuation; it helps explain why the market is wary of assigning value to the pipeline yet.
Commercial Execution and Competition: Coherus is now essentially a one-product commercial company with LOQTORZI (toripalimab) as its sole marketed therapy. While LOQTORZI is FDA-approved for nasopharyngeal carcinoma (NPC), that is a niche indication (NPC is a rare cancer in the U.S.). Sales so far ($10M in Q2 2025) are modest (investors.coherus.com). The real opportunity is to expand toripalimab into broader cancer uses or combinations – but here Coherus faces fierce competition. The PD-1/L1 immunotherapy space is dominated by giants like Merck’s Keytruda and Bristol Myers’ Opdivo, which are entrenched in major cancers like lung, melanoma, etc. Coherus is attempting to carve a space by focusing on combinations (e.g. pairing toripalimab with its CCR8 or IL-27 agents, or with partner drugs) and on indications not fully served by competitors. Still, the company must compete with far larger oncology players for clinical trial enrollment, physician mindshare, and eventual market uptake. Commercial risk: If LOQTORZI cannot differentiate or if payers/providers stick with existing immunotherapies, Coherus could struggle to generate significant revenue. Moreover, Coherus’s newly reduced commercial infrastructure (after layoffs and asset sales) will be tested in promoting LOQTORZI and any future launches. The company cut ~30% of its workforce in early 2024 to streamline operations (www.biospace.com), which helped reduce costs, but could also limit commercial reach. Any missteps in marketing strategy for LOQTORZI – or inability to secure reimbursement and inclusion in treatment guidelines – would be a red flag for its growth prospects. On a positive note, LOQTORZI currently holds a unique niche: it is the only immune checkpoint inhibitor FDA-approved for NPC (www.sec.gov), giving it a monopoly in that small market. The National Comprehensive Cancer Network (NCCN) has included toripalimab in clinical practice guidelines for NPC, which should aid uptake. The risk is that this niche alone is not enough to sustain the company long-term, and expansion will provoke direct competition with well-funded pharma rivals.
Partner and Supply Reliance: Coherus is highly dependent on external partners for its lead product. Toripalimab was licensed from Shanghai Junshi Biosciences – Coherus has U.S./Canada commercial rights via a 2021 collaboration (www.sec.gov) (www.sec.gov). Under this agreement, Junshi is responsible for manufacturing and supplying the drug product while Coherus handles U.S. marketing (www.sec.gov). This reliance poses supply chain and quality risks outside Coherus’s direct control. If Junshi’s production facilities run into regulatory issues or capacity constraints, Coherus could face shortages. (For context, Coherus experienced a serious supply interruption with UDENYCA in late 2024 when a third-party fill/finish contractor over-committed its capacity (www.sec.gov), halting UDENYCA sales for a quarter. Such events highlight the vulnerability to manufacturing partners’ performance.) Similarly, Coherus will depend on Junshi for ongoing co-development of toripalimab in new indications – Junshi is running certain global Phase 3 trials (e.g. in small cell lung cancer) (www.sec.gov) (www.sec.gov) – so Coherus’s progress is partly tied to Junshi’s success. Geopolitical risk also enters: Junshi is a Chinese company, and U.S.-China trade or regulatory frictions (e.g. export restrictions, FDA inspection barriers, etc.) could impact the alliance (www.sec.gov). Any strain in the Coherus–Junshi relationship or failure to meet collaboration milestones would be a major risk factor.
Additionally, Coherus must eventually find partners or buyers for markets outside the U.S. (they out-licensed Canadian toripalimab rights to a firm called Accord/Apotex for a small $6.3M payment (www.sec.gov)). Success internationally is largely in Junshi’s hands or future partners’, adding another layer of uncertainty (www.sec.gov) (www.sec.gov). The royalty and milestone burden in the Junshi deal is also significant: Coherus owes up to $380 million in one-time milestone payments as toripalimab achieves regulatory and sales goals, and a *“low 20s” percent royalty on net sales of LOQTORZI (www.sec.gov). While these payments only occur with success (and high sales), they will trim the profitability of LOQTORZI if it becomes a big seller. Essentially, Coherus must split a sizable portion of toripalimab’s economics with Junshi, which could dampen ultimate margins and cash flows.
Financial and Dilution Risk: Even after recent improvements, Coherus is not yet self-funding through operations**. The company will likely burn tens of millions of dollars per year on R&D (multiple Phase 2 trials, etc.) and the continued launch of LOQTORZI. If pipeline progress is slower or more costly than expected, Coherus may need to raise additional capital sooner than 2027. The 10-K acknowledges that the company “may need to raise additional funds in the future” and cannot guarantee those financings will be successful or on favorable terms (www.sec.gov). Potential avenues include issuing equity (Coherus has an active ATM program with ~$65M capacity remaining (www.sec.gov)), incurring new debt, or licensing out assets for upfront payments. Shareholder dilution is a real possibility – Coherus has already increased its share count via public offerings (e.g. $53.6M equity raised in May 2023 (www.sec.gov)) and the all-stock acquisition of Surface Oncology in 2023 (which brought in the IL-27 program) (www.sec.gov). If its stock remains undervalued, any new equity issuance would be dilutive at these low price levels. Moreover, while the convertible notes are being retired (removing the threat of conversion dilution around $19/share), Coherus did issue warrants or equity in past deals (for example, in the Surface acquisition) – further cap table expansion can’t be ruled out. In short, financing risk is lower in the near-term thanks to the cash pile, but it could return if Coherus accelerates development or does a large Phase 3 trial without a partner.
Another financial red flag is the huge accumulated deficit and historical volatility in earnings. Coherus’s retained losses of $1.6B (www.sec.gov)underscore how much capital has been invested for relatively modest returns so far. While past is past, investors may be cautious that even windfall proceeds have been spent quickly (e.g. prior profitable years were followed by heavy investments and a return to losses). The company’s track record in forecasting and executing is still evolving – for instance, it launched an adalimumab (Humira) biosimilar YUSIMRY in 2023 but ended up selling that franchise in mid-2024 for just $40M (www.sec.gov), suggesting management opted to exit a competitive area rather than scale it. This was arguably a prudent decision, but it also signals how fast strategy can shift, introducing execution risk if plans change.
Regulatory and Other Risks: Coherus faces the standard biotech regulatory risks as well – FDA decisions (for new indications or new molecules) can make or break value. Any safety issues emerging with LOQTORZI or the pipeline drugs could halt development. Intellectual property challenges are also possible (e.g. patent disputes around biotech products or manufacturing). Coherus is involved in complex biologic drugs, so manufacturing quality control (CMC) is an ongoing risk, as seen with the UDENYCA production hiccup. There’s also market adoption risk: persuading oncologists to use a new PD-1 inhibitor (toripalimab) instead of incumbents could be difficult outside of NPC. Coherus will need to generate convincing clinical data to justify toripalimab’s use in combinations or new settings. If those trials only show incremental benefits, physicians might remain loyal to existing therapies, limiting Coherus’s growth.
Finally, macroeconomic conditions (interest rates, risk appetite) can affect Coherus. In a high-rate environment, investors put a heavier discount on long-term biotech payoffs, which can keep valuations depressed. If credit or equity markets tighten by the time Coherus needs funding, that could pose a challenge. On the flip side, positive sector sentiment or a partnership deal (e.g. big pharma licensing one of Coherus’s candidates) could quickly alleviate financing concerns.
Open Questions and Investor Considerations
Will Coherus’s Oncology Bet Pay Off? An open question is whether Coherus can successfully transition from a biosimilar player to a competitive immuno-oncology company. The management narrative at recent conferences has been optimistic – highlighting that Coherus now has a “cash runway through 2026” to hit key data milestones and “unlock large U.S. market potential” if the data are positive (investors.coherus.com) (investors.coherus.com). Investors will want to see concrete evidence: for example, by mid-2026 Coherus should have Phase 1b/2 results for its CCR8 and IL-27 programs. These results will answer whether Coherus’s proprietary combinations with LOQTORZI show compelling efficacy signals (e.g. tumor response rates or progression-free survival improvements). Positive data could de-risk the pipeline and attract a partnership or additional capital at better valuations. A key question is, if the data are positive, does Coherus have the resources to run larger trials on its own? Or would it seek a partner for Phase 3? The answer will affect the long-term value capture for shareholders. Conversely, if data are inconclusive or negative, Coherus might pivot again or face tough choices on how to deploy its cash (perhaps returning some to shareholders or acquiring external assets). This makes 2026 a make-or-break timeframe – investors “can’t miss” those readouts, as they will guide Coherus’s fate.
Can LOQTORZI Gain Ground in a Crowded Field? Another open question is how far Coherus can take LOQTORZI beyond nasopharyngeal carcinoma. The company’s strategy is to grow toripalimab sales in NPC (a small market) while seeking supplemental approvals in other cancers and in combinations (www.nasdaq.com). It has trials ongoing or planned in lung cancer, liver cancer, head & neck cancer, etc., often combining LOQTORZI with another agent (like CHS-114 or Junshi’s TIGIT antibody) (www.sec.gov) (www.sec.gov). Will this approach yield a differentiator that lets toripalimab carve out meaningful share? Big pharma PD-(L)1 inhibitors cover most solid tumor types; for Coherus to break in, it may need either superior efficacy in a subset or a novel combo that competitors don’t have. Investors are watching for signs that LOQTORZI can become more than an “also-ran” PD-1. One clue will be sales trajectory in NPC – if revenue ramps strongly in that niche, it suggests Coherus is executing well and that physicians are receptive (though again, NPC alone has a ceiling). If sales plateau quickly, it raises concern about commercial prowess or the drug’s perceived value. Pricing and reimbursement are also open questions: Coherus hasn’t disclosed LOQTORZI’s price publicly, but as a late entrant PD-1 it may face pricing pressure or need to offer discounts to gain formulary positioning. The oncology landscape is cost-sensitive and crowded; how Coherus navigates this is something investors will learn over the next few quarters of launches and any future label expansions.
How Will the Remaining Cash Be Used? Coherus now has a substantial war chest (~$238M as of mid-2025). Management has outlined that this will fund internal programs through 2026 (investors.coherus.com), but details on capital allocation are sparse. An open question is whether Coherus might deploy some cash for bolt-on acquisitions or in-licensing to augment its pipeline. The hire of a Chief Strategy Officer (Arvind Sood, announced Q4 2025) (stockanalysis.com) suggests the company could be evaluating strategic opportunities. Investors might ask: Is Coherus satisfied with its current three-candidate oncology lineup, or will it look to bring in additional immunotherapy assets to leverage its commercial infrastructure? Since Coherus has experience with business development (e.g. licensing toripalimab from Junshi, acquiring Surface Oncology for pipeline assets), it’s possible they will consider more deals if the right opportunity arises. Using cash for an acquisition could diversify risk but also burn cash faster – the rationale and pricing of any deal will be scrutinized. Alternatively, Coherus might keep the cash largely untouched as a cushion until Phase 2 data arrive, to maintain negotiating strength with potential partners. Capital return (buybacks or dividends) seems highly unlikely in the near term given the need to invest in R&D and the no-dividend policy (www.sec.gov), but down the road (if pipeline succeeds or if Coherus were to sell itself or a product line) that question could arise.
Will the Term Loan Be Paid Off Early? With so much cash on hand, some investors wonder if Coherus will simply pay off the $38.7M term loan to become completely debt-free. The company has not explicitly stated an intention to do so – likely because of the stiff prepayment penalties in the first three years (www.sec.gov). An open question is whether Coherus might retire this loan after May 2027 (when no penalty would apply) if it still has surplus cash. Financially, holding the loan isn’t onerous given interest-only payments, but clearing it would save ~$5M in annual interest. For now, Coherus seems content to let it ride, deploying cash toward growth rather than debt retirement. Investors will monitor this, but it’s a relatively minor point in the grand scheme, provided covenants remain in compliance.
Milestone Upside and Contingent Payments: Coherus is due up to $75 million in future milestone payments from Intas if UDENYCA sales hit certain thresholds (www.biospace.com) (www.biospace.com). It’s uncertain if or when those earn-outs will be achieved – that depends on Intas’s success with the product. Any such payments would be pure upside (and could further extend Coherus’s runway), but given the competitive biosimilar market and the fact Coherus already experienced UDENYCA sales plateauing/declining, these milestones are speculative. Investors likely assign little value to them until realized. Similarly, Coherus owes Junshi milestones as noted; an open question is how it will finance those if they come due. For example, approval milestones ($90M total possible) (www.sec.gov) would presumably be covered by existing cash or future revenues, and sales milestones ($290M max) would ideally be paid out of the high sales themselves. Still, hitting those sales triggers would be a good problem to have (implying toripalimab is a commercial success). The structure of these deals means Coherus’s net cash could fluctuate with such payments – something to be mindful of in long-term projections.
Leadership and Execution: Lastly, an open question is how well Coherus’s leadership – under CEO Denny Lanfear – can execute in a new arena. Lanfear successfully built Coherus’s biosimilar business in the late 2010s, but running an innovative oncology biotech has different challenges (e.g. high-risk science, need for academic KOL engagement, and perhaps partnering with big pharma at some stage). Coherus did bring on new talent (e.g. Chief Scientific Officer Theresa LaVallee, Ph.D., to oversee development (investors.coherus.com)) and is rebranding its identity around oncology. The upcoming investor conferences and scientific meetings will be key opportunities for management to articulate progress. Investors should watch for updates in those forums – for instance, Coherus presenting encouraging interim data at a conference like AACR or ASCO would be a positive sign. Conversely, delays in trial timelines or scarcity of new information at conferences could signal hurdles.
In summary, Coherus’s story is at an inflection point: the company has shored up its finances and is actively courting investors’ attention at key conferences, arguing that the market is undervaluing its oncology pivot. The coming 18–24 months will bring crucial answers regarding its pipeline’s viability. “Don’t miss” Coherus at these events, indeed – for they will likely reveal whether CHRS stock remains a deep-value turnaround play or starts to realize the biotech growth potential that management is striving for.
Sources: Coherus SEC 10-K 2024 (www.sec.gov) (www.sec.gov) (www.sec.gov) (www.sec.gov) (www.sec.gov) (www.sec.gov) (www.sec.gov); Coherus investor presentations & press releases (www.nasdaq.com) (www.globenewswire.com) (coherusbioscience.gcs-web.com) (investors.coherus.com) (investors.coherus.com) (www.biospace.com) (www.globenewswire.com) (www.globenewswire.com) (www.biospace.com) (www.sec.gov) (www.sec.gov); FY2023 and Q2 2025 financial results (www.biospace.com) (investors.coherus.com); BioSpace news on UDENYCA sale and transformation (www.biospace.com) (www.biospace.com); and other relevant filings and reports as cited above.
